Noom GLP-1 Rx Program GLP-1 treatment paired with Noom behavior change Program 2 Includes medication (if prescribed), ongoing care, and full program access
This work was partially supported by National Natural Science Foundation of China 81872915 (M.-W.W.), 82073904 (M.-W.W.), 32071203 (L.H.Z), 81922071 (Y.Z.), 81773792 (D.Y.), 81973373 (D.Y.) and 21704064 (Q.T.Z.)
Discussion GLP-1RAs have changed the therapeutic paradigm of T2D as they significantly improve glucose control, also contributing to pleiotropic effects, especially at the cardiovascular level (60), in different clinical scenarios and therapeutic approaches
In the component of primary outcome, persistent 50% eGFR decline from baseline was significantly reduced in semaglutide group (HR 0.73, 95% CI 0.590.89)
It helps neutralize certain free radicals, while simultaneously supporting your bodys glutathione production